CryoPort (CYRX) AI Stock Analysis

• Market Cap: $525.72M
• Dividend Yield: N/A
• Average Volume (3M): 690.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: -15.86%
• EPS Growth: 66.42%
• Country: US
• Employees: 1,090
• Sector: Industrials
• Sector Strength: 72
• Industry: Integrated Freight & Logistics
• EPS (TTM): -0.18
• Shares Outstanding: 50,068,905
• 10 Day Avg. Volume: 860,552
• 30 Day Avg. Volume: 690,069
• PEG Ratio: -0.03
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 1.63
• P/FCF Ratio: -11.29
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 1.13
• Enterprise Value/Gross Profit: 2.43
• Enterprise Value/Ebitda: -15.30
• 1Y Price Target: $13.63
• Price Target Upside: 47.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $9.50 ▲(3.15% Upside)

CryoPort's overall stock score reflects significant financial challenges, particularly in cash flow generation and profitability. While the earnings call provided a positive outlook with growth in key segments, the technical analysis presents mixed signals, and the valuation metrics suggest potential overvaluation. The company's ability to improve financial performance and manage external risks will be crucial for future stock performance.

Positive Factors

Revenue Growth in Key Segments

Strong growth in critical segments like Life Sciences Services and Products indicates robust demand and market expansion, supporting long-term revenue stability.

Strategic Partnerships

The partnership with DHL enhances CryoPort's logistics capabilities and market reach in APAC and EMEA, strengthening its competitive position.

New Product Launches

Introducing advanced cryogenic systems supports product diversification and technological leadership, driving future growth and market differentiation.

Negative Factors

Declining Revenue Growth

A negative revenue growth trend poses a risk to long-term financial health, indicating challenges in maintaining market share and operational efficiency.

Cash Flow Challenges

Negative cash flow highlights inefficiencies in operations and limits the company's ability to invest in growth opportunities, impacting financial stability.

High Operating Expenses

Elevated operating expenses reduce profitability, challenging the company's ability to improve margins and sustain long-term financial performance.

CryoPort Business Overview & Revenue Model

Company Description

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

How the Company Makes Money

CryoPort generates revenue primarily through its logistics services, particularly the shipping and storage of temperature-sensitive biological materials. Key revenue streams include fees for CryoPort Express® shipping services, which are charged based on the volume and distance of shipments. Additionally, the company earns income from long-term contracts with pharmaceutical and biotechnology companies, which require ongoing logistics support for clinical trials and commercial product distribution. Significant partnerships with leading biopharmaceutical firms enhance its market position and contribute to consistent revenue growth. The company also benefits from increasing demand for advanced therapies, including cell and gene therapies, which require specialized logistics solutions.

CryoPort Financial Statement Overview

Summary

CryoPort faces significant financial challenges, with declining revenues and profitability pressures. While the balance sheet shows some improvement in leverage and return on equity, cash flow generation remains a critical issue. The company needs to focus on improving operational efficiency and cash flow management to enhance its financial health and stability.

Income Statement

CryoPort's income statement reveals a challenging financial landscape. The company has experienced a decline in revenue growth, with a negative growth rate of -6.13% in the TTM period. Despite a relatively healthy gross profit margin of 46.58%, the net profit margin is significantly impacted by high operating expenses, resulting in a negative EBIT margin of -22.88%. The company has managed to achieve a positive net income in the TTM period, but the overall profitability remains weak due to historical losses.

Balance Sheet

The balance sheet shows a moderate financial position with a debt-to-equity ratio of 0.45, indicating manageable leverage. The return on equity has improved to 14.78% in the TTM period, reflecting better utilization of equity. However, the equity ratio stands at 66.28%, suggesting a reliance on equity financing. The company has shown some improvement in its financial stability, but the high level of debt in previous years remains a concern.

Cash Flow

CryoPort's cash flow statement indicates ongoing challenges in cash generation. The operating cash flow is negative, and the free cash flow has declined by -7.46% in the TTM period. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash. Although the free cash flow to net income ratio is positive, it is primarily due to the positive net income rather than strong cash flow generation.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	190.26M	233.25M	237.28M	222.61M	222.61M	78.70M
Gross Profit	88.62M	99.33M	103.87M	96.58M	96.58M	36.33M
EBITDA	-14.10M	-66.36M	-6.19M	-248.91M	-248.91M	-20.31M
Net Income	67.58M	-99.59M	-37.33M	-275.53M	-275.53M	-32.69M
Balance Sheet
Total Assets	773.93M	703.49M	957.74M	1.04B	1.11B	552.40M
Cash, Cash Equivalents and Short-Term Investments	421.31M	261.75M	456.75M	523.32M	628.80M	93.32M
Total Debt	230.86M	250.70M	416.00M	435.91M	427.06M	130.92M
Total Liabilities	261.06M	301.59M	468.72M	482.91M	471.14M	169.71M
Stockholders Equity	515.39M	401.90M	489.02M	555.84M	641.83M	382.70M
Cash Flow
Free Cash Flow	-32.50M	-33.58M	-45.66M	-26.05M	-16.88M	-24.54M
Operating Cash Flow	-14.98M	-16.32M	-757.00K	-1.85M	8.13M	-14.87M
Investing Cash Flow	253.75M	176.81M	36.05M	-59.68M	-469.25M	-382.31M
Financing Cash Flow	-16.91M	-161.53M	-23.80M	-39.17M	564.34M	385.58M

CryoPort Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.21 is below the 20-day moving average (MA) of 9.70, below the 50-day MA of 9.31, and above the 200-day MA of 8.05, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 66.23 is Neutral, neither overbought nor oversold. The STOCH value of 77.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDX	79 Outperform	$72.66B	17.23	15.87%	1.94%	3.09%	14.94%
ZTO	73 Outperform	$17.15B	14.55	13.83%	2.98%	12.89%	3.12%
XPO	70 Outperform	$16.89B	51.70	19.26%	―	-0.30%	-11.02%
GXO	68 Neutral	$6.39B	73.05	2.94%	―	16.94%	-14.01%
JBHT	67 Neutral	$19.56B	35.80	15.13%	0.89%	-1.60%	4.87%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
CYRX	54 Neutral	$525.72M	-9.23	-9.96%	―	-15.86%	66.42%